Semnurpharma - Getting back to normalSemnurpharmaSemnurpharmaSemnurpharma

Getting back to normal

  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Our Culture
  • Partners
  • Chronic Back Pain
    • Chronic Back Pain
    • SP-102 (SEMDEXA™)
    • About our Studies
      • Phase 3 C.L.E.A.R.-2 Study
      • Phase 3 C.L.E.A.R. Study
      • Phase 2 Repeat Dose Study – SP102-03
      • Phase 1 PK/PD and Safety Study – SP-102
      • Pre-Clinical Study – SP-102
  • Science
    • Technology
    • Publications
    • Clinical Trials
  • Investors
    • Investor Overview
    • Presentation
    • News and Events
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
  • Join Our Team
  • Contact Us

Leadership

07
Aug
Date August 7, 2024

Henry Ji, PhD

Henry Ji brings 25+ years of experience in the biotechnology and life sciences industry. Dr. Ji is c...
Read More
Author [email protected]
06
Aug
Date August 6, 2024

Stephen Ma

Stephen Ma serves as the Chief Operating Officer, Chief Financial Officer and Senior Vice President...
Read More
Author [email protected]
05
Aug
Date August 5, 2024

Dmitri Lissin, M.D.

Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, of Semnur Pharmac...
Read More
Author [email protected]
04
Aug
Date August 4, 2024

Suketu D. Desai, PhD

Suketu D. Desai, Ph.D. has 25+ years of experience in the Biologics and Pharmaceutical Industry. Suk...
Read More
Author [email protected]
02
Aug
Date August 2, 2024

Gigi DeGuzman

Gigi DeGuzman is a seasoned professional with over 25 years of experience in human resources, operat...
Read More
Author [email protected]

 

  • Overview
  • Partners
  • Our Culture
  • Product
  • Publications
  • Join Our Team
  • Presentation
  • Contact Us

Connect, follow and have a conversation with us

  • 960 San Antonio Road, Palo Alto, CA, 94303
  • (650) 422-7515
  • [email protected]

Privacy Policy | Terms of Use | © 2026 All rights reserved.